Additional file 3: of B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24Â weeks after initiation of rituximab treatment in rheumatoid arthritis patients

Appendix C. Quantitative tissue uptake of 89Zr-rituximab on whole body PET in responders vs. non-responders. An additional table with SUV of body organs like liver, spleen and vertebrae showing that there is no (significant) difference between responders and non-responders in organ uptake of 89Zr-rituximab. (DOCX 15 kb

Additional file 1: of B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24Â weeks after initiation of rituximab treatment in rheumatoid arthritis patients

Appendix A. Technical PET-CT details. More extensive information and details about the PET-CT scanning procedure and analysis methods. (DOCX 17 kb

Additional file 2: of B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24Â weeks after initiation of rituximab treatment in rheumatoid arthritis patients

Appendix B. Technical details about lymph node biopsy analysis. More extensive information and details about the lymph node biopsy tissue handling and analysis (immunohistochemistry). (DOCX 18 kb

Additional file 1: Table S1. of Physiological evidence for diversification of IFNι- and IFNβ-mediated response programs in different autoimmune diseases

List of 23 type I interferon (IFN) response genes that were measured. Table S2. List of genes that are significantly differentially expressed between patients with systemic lupus erythematosus (SLE) and patients with multiple sclerosis (MS) who were treated with IFNβ. (PDF 116 kb